Alligator immunotherapy-arkiv - BioStock

Clinical effects Alligator's bispecific 4-1bb agonist

Clinical effects observed with Alligator’s 4-1BB agonist

14 March, 2024

Alligator prepares for phase III with CD40 agonist

Alligator prepares for phase III with CD40 agonist

20 February, 2024

Søren Bregenholt CEO Alligator Bioscience

Alligator’s CEO comments on restructuring plan

16 February, 2024

SørenBregenholt, CEO AlligatorBioscience

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

31 January, 2024

Alligator granted US patent for cancer therapy platform

Alligator granted US patent for cancer therapy platform

22 January, 2024

AlligatorBoldVision

Alligator showcases bold drug development vision

8 December, 2023

Alligator_Strong_Q3

Strong Q3 performance for Alligator Bioscience

2 November, 2023

Alligator Biosciece presents mitazalimab data

Data backs up anti-tumour effect of Alligator’s lead asset

5 October, 2023

Alligator CD40 durable

Phase II results indicate durability of response for Alligator’s CD40 agonist

30 June, 2023

Alligator orphan drug designation

Alligator Bioscience awarded Orphan Drug Designation for mitazalimab

25 May, 2023